Published online before print January 15, 2004, doi: 10.1161/01.ATV.0000116863.37311.82
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 American Heart Association, Inc.
Atherosclerosis and Lipoprotein |
Risk of Myocardial Infarction and Stroke in Smokers Is Related to Plasma Levels of Inflammation-Sensitive Proteins
From the Departments of Internal Medicine (P.L., L.S.), Community Medicine (G.E., L.J., B.H.), and Vascular Diseases (F.L.), Malmö University Hospital, Malmö, Sweden.
Correspondence to Dr Peter Lind, Department of Internal Medicine, Malmö University Hospital, S-20502 Malmö, Sweden. E-mail Peter.C.Lind{at}skane.se
Background— The extent to which differences in cardiovascular risk between smokers with similar daily tobacco consumption may be related to plasma levels of inflammation-sensitive proteins (ISP) and whether these proteins are associated with levels of carboxyhemoglobin (COHb%) have not been clarified.
Methods and Results— In a population-based cohort of 1489 never smokers, 1685 former smokers, and 2901 current smokers, aged 28 to 61 years, plasma levels of orosomucoid (
1-acid glycoprotein), 1-antitrypsin, haptoglobin, fibrinogen, and ceruloplasmin were measured. COHb% levels were available for 2098 of them. Incidence of myocardial infarction, stroke, and death were monitored over 18.7±4.7 years. The proportion with high ISP levels (ie, 
2 ISP in the top quartile) increased progressively with daily tobacco consumption (P<0.01) and COHb% (P<0.01). In all smoking categories, the incidence of stroke, cardiac events, and death was related to ISP. In heavy smokers, high ISP levels were associated with adjusted relative risks of 1.57 (1.05 to 2.35) and 1.50 (1.11 to 2.03) for cardiac events and death, respectively. Corresponding figures for moderate and light smokers were 1.59 (1.13 to 2.24) and 1.14 (0.87 to 1.49), respectively, and 1.32 (0.95 to 1.85) and 1.48 (1.10 to 1.98), respectively.
Conclusion— ISP levels are related to COHb% in smokers. High levels are associated with an increased cardiovascular risk.
Key Words: stroke • myocardial infarction • smoking • inflammation • plasma proteins • epidemiology
This article has been cited by other articles:
 |
|
 |
|
  G Engstrom, N Segelstorm, M Ekberg-Aronsson, P M Nilsson, F Lindgarde, and C-G Lofdahl Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study Thorax, March 1, 2009; 64(3): 211 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Chatila, B. M. Thomashow, O. A. Minai, G. J. Criner, and B. J. Make Comorbidities in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 549 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Yanbaeva, M. A. Dentener, E. C. Creutzberg, G. Wesseling, and E. F. M. Wouters Systemic Effects of Smoking Chest, May 1, 2007; 131(5): 1557 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Engstrom, B. Hedblad, M. Rosvall, L. Janzon, and F. Lindgarde Occupation, Marital Status, and Low-Grade Inflammation: Mutual Confounding or Independent Cardiovascular Risk Factors? Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 643 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. MacCallum Markers of Hemostasis and Systemic Inflammation in Heart Disease and Atherosclerosis in Smokers Proceedings of the ATS, April 1, 2005; 2(1): 34 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Hunninghake Cardiovascular Disease in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 44 - 49. [Abstract] [Full Text] [PDF]
|
|